Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

Support from individual and corporate donors fuels the life-improving work of the ALS Network, formerly ALS Golden West. The ALS Network offers hope and help throughout the ALS community by providing ...

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

In some cases, however, brains outlast all other soft tissues and remain intact for hundreds or thousands of years.

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

“There’s an appetite from fans to see the top players in the world going up against each other,” United States general ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the ...

At Lenovo Tech World ’24, global technology leader Lenovo and the Scott-Morgan Foundation (SMF), a non-profit pioneering ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...